- Home
- VVV vs KRYS Comparison
VVV vs KRYS Comparison
Compare VVV & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- KRYS
- Stock Information
- Founded
- VVV 1866
- KRYS 2015
- Country
- VVV United States
- KRYS United States
- Employees
- VVV N/A
- KRYS N/A
- Industry
- VVV Major Chemicals
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VVV Industrials
- KRYS Health Care
- Exchange
- VVV Nasdaq
- KRYS Nasdaq
- Market Cap
- VVV 5.5B
- KRYS 4.5B
- IPO Year
- VVV 2016
- KRYS 2017
- Fundamental
- Price
- VVV $36.23
- KRYS $148.39
- Analyst Decision
- VVV Buy
- KRYS Strong Buy
- Analyst Count
- VVV 9
- KRYS 7
- Target Price
- VVV $45.33
- KRYS $206.67
- AVG Volume (30 Days)
- VVV 1.3M
- KRYS 292.3K
- Earning Date
- VVV 02-04-2025
- KRYS 02-24-2025
- Dividend Yield
- VVV N/A
- KRYS N/A
- EPS Growth
- VVV N/A
- KRYS N/A
- EPS
- VVV 1.61
- KRYS 1.77
- Revenue
- VVV $1,619,000,000.00
- KRYS $241,519,000.00
- Revenue This Year
- VVV $6.61
- KRYS $485.65
- Revenue Next Year
- VVV $12.28
- KRYS $58.64
- P/E Ratio
- VVV $22.22
- KRYS $83.69
- Revenue Growth
- VVV 12.16
- KRYS 2722.80
- 52 Week Low
- VVV $33.86
- KRYS $107.50
- 52 Week High
- VVV $48.27
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- VVV 45.06
- KRYS 37.81
- Support Level
- VVV $36.02
- KRYS $141.72
- Resistance Level
- VVV $37.11
- KRYS $152.94
- Average True Range (ATR)
- VVV 0.79
- KRYS 5.22
- MACD
- VVV 0.23
- KRYS -0.42
- Stochastic Oscillator
- VVV 72.70
- KRYS 33.00
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.